REDWOOD CITY, Calif., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the closing of its previously announced underwritten...

REDWOOD CITY, Calif., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the pricing of its underwritten public offering of...

REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has commenced an underwritten public offering...

-- Robust efficacy with evidence of a dose response ---- 6/6 patients rescue-injection-free in cohort 1, with 3 patients at 52 weeks -- -- 4/6 patients rescue-injection-free in cohort 2 (lower dose) at 24 weeks -- -- Company to host and webcast a discussion with...

-- Presentation of 24-week data from the second cohort and an update from first cohort of patients in the OPTIC trial at Angiogenesis Meeting on Saturday, February 8, 2010 at 2:28 pm EST -- -- Company to host and webcast a discussion with key opinion leaders...

- New headquarters includes 80,000 square feet of office, laboratory, and manufacturing space to advance the development of Adverum’s novel gene therapies - REDWOOD CITY, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a...

-- OPTIC phase 1 trial progressing with plans to complete patient dosing in cohort three, begin enrollment in cohort four in 1Q20 -- -- IND application planned for ADVM-022 in diabetic retinopathy in 1H20; Patient enrollment targeted for 2H20 -- MENLO PARK, Calif.,...

--44 week median follow up for patients (n=6)----Zero anti-VEGF rescue injections required following intravitreal ADVM-022; First patient has reached 52-weeks post treatment----Vision remains stable and anatomical improvements maintained-- MENLO PARK, Calif., Jan. 11,...

MENLO PARK, Calif., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that  the company will present at Piper Jaffray’s...

-- OPTIC phase 1 trial in wet AMD progressing well with dosing of third cohort underway-- -- Company to host conference call today at 1:30 pm PT / 4:30 pm ET-- MENLO PARK, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a...